Latest News and Press Releases

价值 2 亿美元的交易（先期付款） C1 型尼曼-匹克氏病（NPC-1）晚期计划多元临床产品 增加公司对有高度需求的专科疾病的专注 关注孤儿和儿科疾病 预计盈利将于 2019 年开始增加 Sucampo 和 Vtesse 的股东和投资者共同建立支持 NPC 疾病相关研究的基金会 公司将于今天美国东部时间上午 8:30 主持电话会议 马里兰州罗克维尔和盖瑟斯堡, April ...

La transacción está valuada en $200 millones por adelantado Diversifica el proceso de venta con el Programa de etapa avanzada para la enfermedad de Niemann-Pick tipo C1 (NPC-1) Aumenta la atención...

取引価値は前払金額2億ドルニーマン･ピック病C1型 (NPC-1) の後期段階プログラムでパイプラインを多角化大きなアンメットニーズのある希少疾病に企業の焦点を絞る希少疾病および小児疾病への特化を活用2019年以降に収入が拡大される見込みスキャンポおよびヴィテッセの株主および投資者は、NPC疾病に関連する研究をサポートする基金を設立同社は本日午前8時30分 (東部夏時間)...

Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need ...

ROCKVILLE, Md., March 28, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...

ROCKVILLE, Md., March 15, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...

Continued Revenue Growth Leads to Strong Income Growth Company Reiterates 2017 Guidance Company Announces Key Executive Transitions Company to Host Conference Call Today at 8:30 a.m. EST ...

ROCKVILLE, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its fourth quarter and...

ROCKVILLE, Md., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will participate in a fireside...

ROCKVILLE, Md., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), a global biopharmaceutical company, today announced the December 20, 2016 pricing of $260.0 million...